regulation of the EGFR signaling cascade when treated with the EGFR-TKI, Erlotinib. SUM-149 inflammatory breast cancer (IBC) cells, intrinsic Erlotinib resistant MDA-MB-231 non-IBC BC cells ... successfully developed…
Erlotinib has been funded for use as a second and third line treatment of advanced NSCLC since 2006 in Manitoba, Canada. Prior research examined, the cost effectiveness of Erlotinib across ... healthcare system within…
EGFR tyrosine-kinase inhibitors (TKI) such as erlotinib are novel agents in the treatment of lung cancer. However, their efficacy is impaired by the development of drug-resistance through secondary ... this, we show…
Purpose: The acquired resistance to erlotinib, an EGFR tyrosine kinase inhibitor (EGFR-TKI), is a great challenge in the targeted therapy of non-small cell lung cancer (NSCLC). Targeting glutamine ... import could…
Erlotinib is a potent and highly selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase used in the treatment of patients with locally advanced or metastatic non–small cell ... conducted in 36…
explore the effects and possible mechanisms of erlotinib combined with radiotherapy on the proliferation and apoptosis of human non-small cell lung cancer cells. Blank control group, non-small cell ... lung cancer group…
associated with a poor prognosis. Little research has been conducted to directly compare erlotinib with gefitinib regarding the frequency of central nerve system recurrence. This is the first study ... directly compare…
Background Erlotinib, an Epidermal Growth Factor Receptor (EGFR) inhibitor, in combination with gemcitabine was approved in 2005 as 1st-line therapy for patients with Advanced Pancreatic Cancer ... second line setting…
mainstay for advanced NSCLC. In this randomized, single center, phase 2 studies, we investigated erlotinib as first-line therapy plus docetaxel and cisplatin as second-line therapy compared to docetaxel ... cisplatin as…
Context Erlotinib is a selective epidermal growth factor receptor tyrosine kinase inhibitor used as a target therapy against non-small lung cancer and advanced pancreatic cancer. A regimen of erlotinib ... potentially…
growth factor receptor than normal cells, and this affects how they develop and survive. Erlotinib is a drug that blocks epidermal growth factor receptor activity and can treat some lung ... cancers with epidermal…
rather than acquired mutation. Usually, EGFR T790M mutation is resistant to first generation TKI (erlotinib, gefitinib) and sensitive to third generation TKI Osimertinib. Here, we report an EGFR primary T790M ... L858R…
receptor (KDR) gene silencing on the proliferation of A549 cells and their sensitivity to erlotinib. A KDR small interfering RNA (siRNA) sequence was designed and synthesized; then, it was transfected ... colony…
novel bio-analytical method was developed and validated for the quantitative determination of erlotinib in rat serum by using the liquid-liquid extraction extraction chromatography and tandem mass spectrometric…
Simple, rapid, sensitive, accurate, robust & rugged stability indicating analytical method for determination of Erlotinib in pharmaceutical formulations is developed and validated by using UPLC & applied the developed…
effect of epidermal growth factor receptor gene (EGFR) mutation on bevacizumab combined with erlotinib in the treatment of non-small cell lung cancer. Methods: Fifty-nine patients with non-small ... mutant group (n=59)…
Erlotinib is used for the treatment of lung and pancreatic cancer. The clinical usage of erlotinib is limited due to its poor solubility and dissolution rate. The objective ... research work is to formulate erlotinib…
fewer adverse effects. Patients and methods: We present a lung cancer patient with erlotinib associated severe liver toxicity and perform a systemic review on published studies that report EGFR ... days after EGFR-TKI…
effects and molecular mechanism of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib on NKG2D ligand expression in human lung adenocarcinoma A549 cells and the cytotoxicity of cytokine…
Erlotinib, a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor has been approved by FDA for patients with pancreatic cancer and non-small cell lung cancer. Skin rash ... associated with…
rationale and design of a Phase III, randomized, double-blind study of dacomitinib versus erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) following one or two prior
report a case with NSCLC complicated with brain metastasis in which the initiation of erlotinib treatment resulted in recurrence of seizure due to a decreased blood phenytoin level
progressed on three prior therapies, has an excellent and durable response to bevacizumab and erlotinib. Our case illustrates the importance of recognizing papillary renal cell carcinoma and mutational testing since
Context The combination of gemcitabine and erlotinib is a standard first-line treatment for unresectable, locally advanced or metastatic pancreatic cancer. We reviewed our single centre experience to assess ... advanced…
prepared by cost effective reagents and using these formamidines, prepared anticancer agents Gefitinib and Erlotinib, approved by US FDA for the treatment of non-small-cell-lung cancer and pancreatic
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.